Fabrizio Presicce1, Cosimo De Nunzio1, Andrea Tubaro2. 1. Department of Urology, Sant'Andrea Hospital, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00198, Rome, Italy. 2. Department of Urology, Sant'Andrea Hospital, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00198, Rome, Italy. andrea.tubaro@uniroma1.it.
Abstract
PURPOSE OF REVIEW: We have reviewed the available evidence on the impact of long-term pharmacological treatment of lower urinary tract symptoms on the outcomes of benign prostatic hyperplasia surgery. EVIDENCE ACQUISITION: A systematic literature search from January 1990 to May 2017 was performed. Only references in the English language and peer-reviewed manuscripts were considered. RECENT FINDINGS: Over time, the ever-increasing use of long-term pharmaceutical treatments has considerably reduced the rate of BPH surgery in most countries. In addition, patients undergoing surgery are now generally older, more fragile and with larger prostates. Nevertheless, progress in the surgical field may have compensated for this critical picture and no pejorative trend has been recorded in peri- and post-operative complications and functional outcomes. The question whether long-term pharmacological treatment has altered the outcomes of surgical interventions of BPH remains with no clear answer. The call for randomized studies of long-term pharmacological vs surgical treatment of lower urinary tract symptoms due to BPH pharmacological treatment remains valid.
PURPOSE OF REVIEW: We have reviewed the available evidence on the impact of long-term pharmacological treatment of lower urinary tract symptoms on the outcomes of benign prostatic hyperplasia surgery. EVIDENCE ACQUISITION: A systematic literature search from January 1990 to May 2017 was performed. Only references in the English language and peer-reviewed manuscripts were considered. RECENT FINDINGS: Over time, the ever-increasing use of long-term pharmaceutical treatments has considerably reduced the rate of BPH surgery in most countries. In addition, patients undergoing surgery are now generally older, more fragile and with larger prostates. Nevertheless, progress in the surgical field may have compensated for this critical picture and no pejorative trend has been recorded in peri- and post-operative complications and functional outcomes. The question whether long-term pharmacological treatment has altered the outcomes of surgical interventions of BPH remains with no clear answer. The call for randomized studies of long-term pharmacological vs surgical treatment of lower urinary tract symptoms due to BPH pharmacological treatment remains valid.
Authors: Se Young Choi; Tae-Hyoung Kim; Soon Chul Myung; Young Tae Moon; Kyung Do Kim; Young Sun Kim; Hye-Ryoun Kim; In Ho Chang Journal: Korean J Urol Date: 2012-01-25
Authors: Salvatore D'Agate; Chandrashekhar Chavan; Michael Manyak; Juan Manuel Palacios-Moreno; Matthias Oelke; Martin C Michel; Claus G Roehrborn; Oscar Della Pasqua Journal: World J Urol Date: 2020-12-18 Impact factor: 4.226